This is the latest update on Cogaane from the PDpipeline database --

"A phase I safety study was completed successfully in 2003.

A grant from the Michael J Fox Foundation in 2008 will fund additional preclinical research to determine the optimal dosing requirements and duration of treatment for Cogane, and will help "gain essential information on the appropriate dosing and design for a Phase II clinical study in Parkinson’s disease patients. "

In May 2008 company stated on an earnings conference call, Phase II clinical trial could begin "towards the end of the year."

In April 2009, Phytopharm announced the commencement of a safety, tolerability and pharmacokinetic (PK) study of PYM50028 (Cogane), which will involve both healthy volunteers and patients with Parkinson’s disease (PD)."

The new phase I study is recruiting participants in the UK, according to the clinicaltrials.gov record.
"Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients"

Contacts
Contact: Joanna M Locker, Mrs. 01480 437697 ext 962 jlocker@phytopharm.com
Contact: Darren J Kember, Mr. 01480 437697 ext 964 dkember@phytopharm.com


Locations
United Kingdom, Cambridgeshire
LCG Bioscience Recruiting
Bourn, Cambridgeshire, United Kingdom, CB23 2TN


http://clinicaltrials.gov/ct2/show/N...=cogane&rank=1



http://apexutf.shellprompt.net/pls/a..._PAGE:176%2C12